Design of a phase 3, prospective, multicenter, open-label study of safety and hemostatic efficacy of rurioctocog alfa pegol in previously untreated patients <6 years of age with severe hemophilia A

被引：0
|
作者：
Mullins, E. [1 ,2 ]
Kefurt, C. [3 ]
Engl, W. [3 ]
Tangada, S. [4 ]
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[3] Shire, Vienna, Austria
[4] Shire, Lexington, MA USA
来源：
HAEMOPHILIA | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P095
引用
收藏
页码：83 / 83
页数：1
相关论文
共 50 条
  • [1] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study
    Sidonio, Robert F.
    Thompson, Alexis A.
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Antmen, Ali Bulent
    Maggiore, Caterina
    Engl, Werner
    Ewenstein, Bruce
    Tangada, Srilatha
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (10) : 793 - 801
  • [2] Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial
    Sidonio, Robert F., Jr.
    Knoll, Christine
    Peyvandi, Flora
    Stasyshyn, Oleksandra
    Antmen, Ali Bulent
    Yeoh, Seoh Leng
    Sosothikul, Darintr
    Maggiore, Caterina
    Engl, Werner
    Allen, Geoffrey
    Tangada, Srilatha
    BLOOD, 2021, 138
  • [3] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study (vol 16, pg 793, 2023)
    Sidonio, R. F.
    Thompson, A. A.
    Peyvandi, F.
    Stasyshyn, O.
    Yeoh, S. L.
    Sosothikul, D.
    Antmen, A. B.
    Maggiore, C.
    Engl, W.
    Ewenstein, B.
    Tangada, S.
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (1-3) : 101 - 101
  • [4] EFFICACY AND SAFETY OF RURIOCTOCOG ALFA PEGOL IN PERIOPERATIVE MANAGEMENT: INTERIM RESULTS FROM AN OPEN-LABEL MULTICENTER CLINICAL TRIAL IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A
    Peyvandi, F.
    Sidonio, R. F., Jr.
    Stasyshyn, O.
    Alamelu, J.
    Glosli, H.
    Le, P. -Q.
    Albayrak, C.
    Antmen, A. B.
    Lopez, M. Fernandez
    Maggiore, C.
    Engl, W.
    Tangada, S.
    HAEMOPHILIA, 2022, 28 : 48 - 48
  • [5] Efficacy and Safety Results from a Phase 3b, Open-Label, Multicenter, Continuation Study of Rurioctocog Alfa Pegol for Prophylaxis in Previously Treated Patients with Severe Hemophilia A
    Mullins, Eric S.
    Konkle, Barbara A.
    McGuinn, Catherine E.
    Engl, Werner
    Tangada, Srilatha D.
    BLOOD, 2018, 132
  • [6] PHASE 3B, OPEN-LABEL, MULTICENTER, CONTINUATION STUDY OF RURIOCTOCOG ALFA PEGOL FOR PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
    Alvarez Roman, M. T.
    Mullins, E.
    Chowdary, P.
    Stasyshyn, O.
    Zhang, J.
    Engl, W.
    Tangada, S.
    HAEMATOLOGICA, 2019, 104 : 112 - 113
  • [7] Results from a phase 3B, open-label, multicenter, continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe hemophilia A: Analysis by age group
    Chowdary, P.
    Mullins, E.
    Stasyshyn, O.
    Zhang, J.
    Engl, W.
    Tangada, S.
    HAEMOPHILIA, 2019, 25 : 158 - 159
  • [8] Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a
    Sidonio, Robert F., Jr.
    Thompson, Alexis A.
    Peyvandi, Flora
    Albayrak, Canan
    Yeoh, Seoh Leng
    Lam, Joyce
    Maggiore, Caterina
    Engl, Werner
    Allen, Geoffrey
    Tanada, Srillatha
    BLOOD, 2021, 138
  • [9] Results from a phase 3b, open-label, multicenter, CONTINUATION study of Rurioctocog Alfa Pegol for prophylaxis in previously treated patients with severe hemophilia A: Analysis by US age categories
    Mullins, E.
    Chowdary, P.
    Stasyshyn, O.
    Zhang, J.
    Engl, W.
    Tangada, S.
    HAEMOPHILIA, 2019, 25 : 48 - 49
  • [10] Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients
    You, Chur Woo
    Baek, Hee Jo
    Park, Sang Kyu
    Park, Young Shil
    Shin, Ho-Jin
    Engl, Werner
    Tangada, Srilatha
    BLOOD RESEARCH, 2019, 54 (03) : 198 - 203
12345